Selective serotonin-reuptake inhibitor-induced movement disorders

Annals of Pharmacotherapy

Volumn 32, Issue 6, 1998, Pages

  Gerber, Patricia E ^a,b   Lynd, Larry D ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

^c Brit Columbia Reg Adverse Drug R   (Canada)

Author keywords

Movement disorders; Selective serotonin reuptake inhibitors

Indexed keywords

BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AKATHISIA; ARTICLE; BRUXISM; DISEASE DURATION; DISEASE PREDISPOSITION; DYSKINESIA; DYSTONIA; FEMALE; HUMAN; MALE; MORBIDITY; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

AKATHISIA, DRUG-INDUCED; BRUXISM; DEPRESSION; DYSKINESIA, DRUG-INDUCED; DYSTONIA; FEMALE; HUMANS; MALE; PARKINSON DISEASE, SECONDARY; SEROTONIN UPTAKE INHIBITORS;

EID: 14444272517     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17302     Document Type: Article

References (51)

1. Leo RJ, Lichter DG, Hershey LA. Parkinsonism associated with fluoxetine and cimetidine: a case report. J Geriatr Psychiatry Neurol 1995;8: 231-3.
2. Por CP, Watson L, Doucette D, Dolovich L. Sertraline-associated bruxism. Can J Clin Pharmacol 1996;3:123-5.
3. Fitzgerald K, Healy D. Dystonias and dyskinesias of the jaw associated with the use of SSRIs. Hum Psychopharmacol 1995;10:215-9.
4. Lazowick AL, Levin GM. Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother 1995;29:1284-5.
5. Baldwin D, Fineberg N, Montgomery S. Fluoxetine, fluvoxamine and extrapyramidal-tract disorders. Int Clin Psychopharmacol 1991;6:51-8.
6. LaPorta LD. Sertraline-induced akathisia. J Clin Psychopharmacol 1993; 13:219-20.
7. Lipinski JF, Mallya G, Zimmerman P, Pope HG. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50:339-42.
8. Opler LA. Sertraline and akathisia. Am J Psychiatry 1994;151:620-1.
9. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449-54.
10. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989;146:399-400.
11. Poyurovsky M, Meerovich I, Weizman A. Beneficial effects of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive - compulsive patient. Int Clin Psychopharmacol 1995;10:111-4.
12. Rothschild AJ, Locke CA. Re-exposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991;52:491-3.
13. Adler LA, Angrist BM. Paroxetine and akathisia. Biol Psychiatry 1995; 37:336-7.
14. Lesaca TG, Fluvoxamine and akathisia. J Clin Psychopharmacol 1996; 16:334.
15. Murray V. Laryngeal dystonia. Br J Psychiatry 1995;167:698-9.
16. Rone LA, Ferrando SJ. Serotonin reuptake inhibitor - related extrapyramidal side effects in two patients with cerebral palsy, Psychosomatics 1996;37:165-6.
17. Marchioni E, Perucca E, Soragna D, Bo P, Malaspina A, Ferrandi D, et al. Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. Am Acad Neurol 1996;46:853.
18. Data on file. British Columbia Regional Adverse Drug Reaction Reporting Program. Vancouver, BC, Canada. December 1996.
19. Mander A, McCausland M, Workman B, Flamer H, Christophidis N. Fluoxetine induced dyskinesia. Aust N Z J Psychiatry 1994;28:328-30.
20. Bouregeois JA, Klein M. Paroxetine and tardive dyskinesia (letter). J Clin Psychopharmacol 1996;16:258.
21. Dave M. Fluoxetine-associated dystonia (letter). Am J Psychiatry 1994; 151:149.
22. Clarke CE, Bamford JM, House A. Dyskinesia in Creutzfeldt - Jakob disease precipitated by antidepressant therapy. Mov Disord 1992;7:86-7.
23. Stein MH. Tardive dyskinesia in a patient taking haloperidol and fluoxetine (letter). Am J Psychiatry 1991;148:683.
24. Bharucha KJ, Sethi KD. Complex movement disorders induced by fluoxetine. Mov Disord 1996;11:324-6.
25. Sandler NH. Tardive dyskinesia associated with fluoxetine (letter). J Clin Psychiatry 1996;57:91.
26. Dubovsky SL, Thomas M. Tardive dyskinesia associated with fluoxetine. Psychiatr Serv 1996;47:991-3.
27. Meco G, Bonifiati V, Fabrizio E, Vanacore N. Worsening of parkinsonism with fluvoxamine - two cases. Hum Psychopharmacol 1994;9:439-41.
28. Al-Adwani A. Brain damage and tardive dyskinesia. Br J Psychiatry 1995;167:410-1.
29. Chouinard G, Sultan S. A case of Parkinson's disease exacerbated by fluoxetine. Hum Psychopharmacol 1992;7:63-6.
30. Jansen Steur ENH. Increase of Parkinson disability after fluoxetine medication. Neurology 1993;43:211-3.
31. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989;146:1352-3.
32. Thomas P, Roche J, Maron M, Cotencin O, Vaiva G, Goddernand M. Severe extrapyramidal symptoms with fluvoxamine despite neuroleptic withdrawal. Eur Psychiatry 1996;11:273.
33. Cano A, Roquer J. Parkinsonism secondary to the use of sertraline. Med Clin (Bare) 1995;105:797-8.
34. Singh RK, Gupta AK, Singh B. Acute organic brain syndrome after fluoxetine treatment. Am J Psychiatry 1995;152:295-6.
35. Gernaat HB, Van de Woude J, Touw DJ. Fluoxetine and parkinsonism in patients taking carbamazepine. Am J Psychiatry 1991;148:1604-5.
36. Wils W. Extrapyramidal symptoms in a patient treated with fluvoxamine. J Neurol Neurosurg Psychiatry 1992;55:330-1.
37. Berk M. Paroxetine induced dystonia and parkinsonism in obsessive compulsive disorder. Hum Psychopharmacol 1993;8:444-5.
38. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979;45:165-75.
39. Oslin DW, Duffy K. Dyskinesia associated with fluvoxamine. J Clin Psychopharmacol 1993;13:365-6.
40. Ellison JM, Stanziani P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 1993;54:432-4.
41. Budman CL, Bruun RD. Persistent dyskinesia in a patient receiving fluoxetine (letter). Am J Psychiatry 1991;148:1403.
42. Chong SA. Fluvoxamine and mandibular dystonia. Can J Psychiatry 1995;40:430-1.
43. Haenel T, Stockli HR, Truog P. A case of rare side effects of particular antidepressants (abstract). Nervenarzt 1995;66:70-2.
44. Marques C, Figeueira I, Nardi AE, Mendlowicz M, Coscarelli P, Andrade Y, et al. Acute dystonic reaction with fluoxetine: case report (abstract). J Bras Psiquiatr 1996;45:51-4.
45. Gatto EM, Fernandez Paral M, Micheli F. Increase of Parkinson disability after fluoxetine medication (abstract). Medicina 1994;54:182.
46. Keppel Hesselink JM, Touw DJ, Gernaat HBPE, Van de Woude J, Jansen ENH, Kolling P. Parkinsonism following addition of fluoxetine to the treatment with neuroleptics or carbamazepine (abstract). Ned Tijdschr Geneeskd 1992;136:754-6.
47. Daric C, Dollfus S, Mihout B, Omnient Y, Petit M. Fluoxetine et symptomes extrapyramidaux: a propos de deux observations (abstract). Encephale 1993;19:61-2.
48. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994;114:559-65.
49. Wells BG, Hayes PE. Depressive illness. In: DiPiro JT, Talbert RL, Hayes PE, Yee GC, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. New York: Elsevier, 1989:748-64.
50. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press, 1990:383-435.
51. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992;53:278-82.